Fundraising FoxF-Prime Capital — 2016 Investments
10 investments dated 2016 · listed companies and verified rows first · show all
Eywa Pharma develops and manufactures generic drugs across multiple therapeutic areas and dosage forms, including tablets, capsules, and oral suspensions, for patients and pharmacies.
Advanced ManufacturingBiotechHealthtechMedical DevicesSingapore, SG
BoardKetan Patel(Director)in
Axoni provides a distributed ledger platform for post-trade processing and settlement in financial markets, serving institutional clients in capital markets operations.
Crypto & Web3Data & InfrastructureEnterprise SoftwareFintechSaaSNew York City, US
Greg Schvey(CEO)Jeffrey Schvey(CTO)inGreg (CEO)(Chief Executive Officer)Jeff (CTO)(Chief Technology Officer)Lindsay Drabczyk(People Operations Manager)Kristina Karcic(People)
Co-investorsAndreessen HorowitzCoatue ManagementCommunitas Capital PartnersDCVC (Data Collective)Digital Currency GroupY Combinator+16 more
Benchling provides a cloud-based R&D platform for life sciences, combining a collaborative electronic lab notebook, structured scientific data modeling, automated workflows, and AI tools.
AI & Machine LearningBiotechEnterprise SoftwareSaaSSan Francisco, US
Sajith Wickramasekara(CEO)inAshutosh Singhal(Founder)Ashu Singhal(Founder)inCheng Kang(Founder)Cornelius Chen(Founder)Cory Liin
Co-investorsAlkeon InnovationAndreessen HorowitzArtisanal VenturesBalaji SrinivasanDraper AssociatesEnsemble Labs+31 more
Core Diagnostics offers diagnostic laboratory testing with sample collection services, including routine tests and diagnostic monitoring tests scheduled at defined intervals.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsArtiman VenturesEight Roads Ventures
Eywa is a team of scientists and innovators focused on advancing mental health through research and partnerships.
BiotechDeep TechDigital HealthHealthtechMental Health
Co-investorsDraper AssociatesGanesha LabGRIDXah! Ventures
Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.
BiotechDigital HealthHealthtechCambridge, US
PETER M. HECHT(Executive Officer, Director)inMARK G. CURRIE(Executive Officer)inHALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)in
BoardTERRANCE G. MCGUIRE(Director)
Co-investorsMountain Group CapitalRidgeback CapitalVenrockMaverick VenturesPolaris Partners
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture InvestmentsRho Ventures+3 more
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCForesite CapitalUCL Technology Fund4BIO CapitalAgent CapitalBaillie Gifford+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.